20 March 2009
Sue Sutter
A US FDA advisory panel has endorsed Johnson & Johnson/ Bayer's oral anticoagulant Xarelto (rivaroxaban) for the short-term prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, despite liver safety questions.
In...
Please Login to read the full article.
RELATED CONTENT
ANALYSIS
Other Informa Analysis
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
